stage IIIC (S: 36 m, S-GIII: 39 m, S: 43 m, U-GIII: 48 m, E-GIII: 68 m), and 1 pts was stage IIIB (S-GIII: 31 m).

Relevant toxicities: Emesis (grade III, 19/62 cy; IV, 1/62 cy); mucositis (III, 1/62 cy); diarrhea (III, 4/62 cy; IV, 7/58 cy); neuro-constipation (III–IV, 6/62 cy). Median duration of grade IV neutropenia and thrombocytopenia, 11 d (6–20 d) and 13 d (3–23 d). Fever (58/62 cy). There were 3 toxic deaths (8.5%).

Conclusions: These results suggest that a subset of patients with poor prognosis AOC might benefit from the HD-DICEP treatment. The toxicity profile does not differ from previously reported series.

936 POSTER

Treatment of advanced ovarian cancer by cytoreductive surgery associated with intra peritoneal hyperthermic perfusion

M. Vaglini, N. Santoro, M.G. Inglese, D. Carlier Somers, S. Guadagni, O. Carraro, M. Deraco. *National Cancer Institute, Surgery D, Milan, Italy*

Introduction: The role of appropriate and extensive surgery to treat ovarian cancer was stressed by different Authors. Cytoreductive Surgery (CS) that consists in a complete removal of all tumor dissemination, is associated with longer survival either in the management of primary or recurrent ovarian cancer. The conventional approach to primary ovarian cancer with surgery and systemic chemotherapy permits to achieve complete responses in 20–40% of treated patients. Second line chemotherapy responses ranges from 22–37% but the prognosis remain poor (median survival 43–61 weeks).

Procedures: In a phase II clinical study, 26 patients with advanced ovarian cancer were treated by CS and Intra Peritoneal Hyperthermic Perfusion (IPHP). All patients were treated before by surgery (mean 2 procedures) and systemic CT (mean 3 scheduled treatments). In 16 patients a diffuse peritoneal carcinomatosis (PC) was observed; remaining 10 patients presented a limited PC. Cytoreductive surgery was conducted in 15 patients that received partial peritonectomy, and intestinal resection was done in 9 patients. The IPHP was carried out with the closed abdomen technique, using a preheated polysaline perfusate containing CDDP (mean 250 mg) and MMC (mean 30 mg) using a heart-lung pump at a mean flow of 700 ml/min for 60 minutes from the true hyperthermia phase (42.5°C). Fifteen patients had macroscopic complete resection of the tumor by CS while in 11 patients a residual disease ranging from 0.25 to 5 cm remained.

Results: Two-year overall survival is 55%; one-year overall disease-free survival is 60%, while one-year local control was obtained in 73% of treated patients. The overall survival is correlated to the completeness of cytoreduction ($P < 0.001$), the Karnofsky status ($P = 0.0018$) and the extension of peritoneal carcinomatosis ($P = 0.028$).

Conclusions: Patients with peritoneal carcinomatosis of ovarian cancer are responsive to combined treatments (CS + IPHP) even if heavily pretreated. The aggressive and complete surgery enables us to obtain a minimal or microscopic residual disease curable with the contemporaneous administration of high temperature and high drug concentration. Further clinical trials could define the role of this approach in the early phase of treatment of ovarian cancer. This study was partially supported by the Associazione Italiana per la Ricerca sul Cancro.

937 POSTER

Docetaxel-vinorelbine combination for platinum resistant paclitaxel pretreated ovarian cancer. A hellenic co-operative oncology group phase II study

G. Aravantinos[1], D. Bafaloukos[1], M.A. Dimopoulos[1], C. Nikolaides[1], P. Papakostas[1], Ch. Kiamouris[1], K. Sikiotis[1], T. Rapsomaniki[1], G. Fountzilas[1], D.V. Skarlos[1]. [1]*Hellenic Co-operative Oncology Group, Athens, Greece*

Purpose: Prognosis of relapsed ovarian cancer (OC) patients resistant to platinum is very poor and the treatment of choice has not been defined yet. Vinorelbine was proven effective in OC, while docetaxel is highly effective and appears not totally cross resistant with paclitaxel.

Methods: Eligible are patients with relapsed OC resistant to platinum and previously treated with paclitaxel. Chemotherapy is consisted of Docetaxel at 70 mg/m^2 (day 8) and Vinorelbine at 25 mg/m^2 (days 1.8), repeated every 3 weeks. Up to 2 previous platinum-based regimens are allowed.

Results: So far 22 patients entered the study, with a median age of 59 (43–72) years. The mean number of previous regimens is 1.5 and the median chemotherapy-free interval was 4.7 (0–6) months. Toxicity was considerable, mainly leucopenia-neutropenia (70% of patients), anaemia (58%), neurotoxocity (35%) and alopecia, while severe toxicities included leucopenia-neutropenia (24% of patients). Dose reduction was performed in 17% of patients. There are not treatment-related deaths. So far 13 patients are evaluable for response. Three patients achieved partial response lasting from 3+ to 7+ months, while another 3 patients demonstrated stabilization of their disease.

Conclusions: Our preliminary results appear quite encouraging.

938 POSTER

Paclitaxel, cisplatin and epirubicin (PCE) combination chemotherapy for newly diagnosed patients with advanced epithelial ovarian cancer (AEOC)

C. Papadimitriou[1], A. Anagnostopoulos[1], Z. Voulgaris[2], G. Vlahos[2], E. Kioses[2], T. Akrivos[2], M. Dimopoulos[1]. [1]*Department of Clinical Therapeutics;* [2]*First Department of Obstetrics and Gynecology, University of Athens School of Medicine, Athens, Greece*

Purpose: To evaluate the activity and toxicity of the PCE combination after cytoreductive surgery in patients with AEOC.

Methods: Forty consecutive patients with AEOC (7 optimally and 33 suboptimally debulked) were treated with paclitaxel 135 mg/m^2 as a 3 hour intravenous infusion, cisplatin 75 mg/m^2 IV, and epirubicin 50 mg/m^2 IV every 3 weeks on an outpatient basis.

Results: Among 29 patients with measurable disease, 24 (83%) achieved an objective response including 19 complete and 5 partial responses. Among 18 patients who underwent second-look laparotomy, pathological complete remission was confirmed in 9 (50%). With a median follow-up period of 34 months the overall median survival has not been reached yet. The median remission duration was 14 months, and the median time to progression for patients with measurable disease was 17 months. The treatment was well tolerated; the most common toxicity was neutropenia (WHO grade 3 + 4) which occurred in 30% of patients. Neuropathy (grade ≥ 2) developed in only 8% of patients.

Conclusion: PCE at the dose levels given is an active and welltolerated outpatient regimen in the treatment of AEOC.

939 POSTER

Phase I study of repetitive high-dose topotecan (T) carboplatin (C) and paclitaxel (P) in previously untreated ovarian cancer

D. Rischin, M. Prince, M. Quinn, D. Allen, R. Planner, J. Davison, P. Gates. *Peter MacCallum Cancer Institute, Melbourne, Australia*

Purpose: In view of the significant activity of T in ovarian cancer with dose limiting toxicity of myelosuppression, we evaluated the addition of T to C and P with peripheral blood progenitor cell support.

Methods: Patients received 2 cycles of C AUC 5 and P 175 mg/m^2 with collection of progenitor cells after the second cycle. They then received 3 cycles of intensive therapy with T on a daily × 5 schedule, P 250 mg/m^2 (24 hr) on day 3 and C AUC 12 on day 4. Eligibility included previously untreated stage 3 or 4 ovarian cancer with either macroscopic residual disease following primary debulking surgery or clear cell histology.

Results: 14 patients, median age – 49 (range 21–63). T was escalated in 4 patient cohorts up to a dose of 3.5 mg/m^2/d. This dose level met the criteria for defining the dose limiting dose level with 2/4 patients experiencing grade 4 mucositis. The preceding dose level with T 2.5 mg/m^2/d is the recommended dose. Toxicities in the 3 patients treated at this dose level were grade 3 mucositis in 1/9 high dose cycles and febrile neutropenia in 2/9. Responses in 14 patients who have had second look laparoscopy or laparotomy: pathologic CR – 7, microscopic residual – 1, PR – 5, PD – 1.

Conclusion: When combined with C (AUC 12) and P (250 mg/m^2) the recommended topotecan dose is 2.5 mg/m^2/day. This outpatient high dose regimen combines 3 of the most active drugs in ovarian cancer with acceptable toxicity and promising activity.

940 POSTER

Adherence to a regional guideline for treatment of malignant epithelial ovarian carcinoma

P. Ottevanger[1], L. Beex[1], R. Grol[2], P. De Mulder[1]. [1]*Department Medical Oncology;* [2]*Department General Practice, University Hospital Nijmegen, Netherlands*

Purpose: to study quality of chemotherapy for malignant epithelial ovarian carcinoma (OC) according to a guideline in a university hospitall.